Back to results
US 4,933,179 AGranted
Feline leukemia virus antigen vaccines
AssigneeSyntex (U.S.A.) Inc.
InventorsAnthony C. Allison, Noelene E. Byars
Life of this patent
Estimating the term…
Abstract
A vaccine for immunizing animals against Feline Leukemia Virus (FeLV) infections contains an FeLV antigen emulsified with a polyoxypropylene-polyoxyethylene block polymer, a glycol ether-based surfactant, an immunopotentiating amount of an immunostimulating glycopeptide, and, optionally, a metabolizable non-toxic oil.
Claims26
A vaccine for immunizing an animal against feline leukemia virus, which vaccine comprises:
- (a) an immunologically effective amount of an FeLV antigen;
- (b) an immunopotentiating amount of an immunostimulating glycopeptide, wherein said glycopeptide is a compound of the formula ##STR4## wherein R and R.sup.1 are the same or different and are hydrogen or acyl containing from 1 to 22 carbon atoms;
- R.sup.2 is an unsubstituted or substituted alkyl radical containing from 1 to 22 carbon atoms, or an unsubstituted or substituted aryl radical containing from 6 to 10 carbon atoms;
- R.sup.3 is hydrogen, alkyl, or aryl of 7 to 10 carbon atoms;
- R.sup.4 is hydrogen or alkyl;
- X is alanyl, valyl, leucyl, isoleucyl, .alpha.-aminobutyryl, threonyl, methionyl, cysteinyl, glutamyl, glutaminyl, aspartyl, phenylalanyl, tyrosyl, tryptophanyl, lysyl, ornithinyl, arginyl, histidyl, asparginyl, prolyl, hydroxyprolyl, seryl, or glycyl,
- R.sup.5 and R.sup.6 are the same or different and are a carboxyl group, a carboxyl group esterified with a lower alkanol, or a carbamoyl group, which, on the nitrogen atom, is unsubstituted or mono-substituted or di-substituted by alkyl, aryl, aralkyl, alkylidene, or carbamoylmethyl;
- (c) a multi-phase-forming amount between 0.2 and 49% v/v of the vaccine of a non-toxic polyoxypropylene-polyoxyethylene block polymer, wherein said block polymer is liquid over a temperature range between about 15.degree.-40.degree. C., has a polyoxypropylene midsection of molecular weight between about 2250 and 4300, and has polyoxyethylene in an amount between about 1 and 30% of the block polymer;
- (d) a multi-phase-stabilizing amount between 0.05 and 2.5% v/v of the vaccine of a glycol ether-based surfactant;
- and
- (e) buffered saline in a quantity sufficient to make volume.
8 more elements
The vaccine of claim 25 which further comprises a non-toxic metabolizable oil, present in an amount of 1-30% (w/v).
A method for enhancing the immunogenicity of an FeLV antigen which method comprises combining
- an immunologically effective amount of an FeLV antigen with an adjuvant composition comprising:
- an immunopotentiating amount of an immunostimulating glycopeptide, wherein said glycopeptide is a compound of the formula ##STR5## wherein R and R.sup.1 are the same or different and are hydrogen or acyl containing from 1 to 22 carbon atoms;
- R.sup.2 is an unsubstituted or substituted alkyl radical containing from 1 to 22 carbon atoms, or an unsubstituted or substituted aryl radical containing from 6 to 10 carbon atoms;
- R.sup.3 is hydrogen, alkyl, or aryl of 7 to 10 carbon atoms;
- R.sup.4 is hydrogen or alkyl;
- X is alanyl, valyl, leucyl, isoleucyl, .alpha.-aminobutyryl, threonyl, methionyl, cysteinyl, glutamyl, glutaminyl, aspartyl, phenylalanyl, tyrosyl, tryptophanyl, lysyl, ornithinyl, arginyl, histidyl, asparginyl, prolyl, hydroxypropyl, seryl, or glycyl;
- R.sup.5 and R.sup.6 are the same or different and are a carboxyl group, a carboxyl group esterified with a lower alkanol, or a carbamoyl group, which, on the nitrogen atom, is unsubstituted or mono-substituted or di-substituted by alkyl, aryl, aralkyl, alkylidene, or carbamoylmethyl;
- a multi-phase-forming amount between 0.2 and 49% v/v of the vaccine of a non-toxic polyoxypropylene-polyoxyethylene block polymer, wherein said block polymer is liquid over a temperature range between about 15.degree.-40.degree. C., has a polyoxypropylene midsection of molecular weight between about 2250 and 4300, and has polyoxyethylene in an amount between about 1 and 30% of the block polymer;
- a multi-phase-stabilizing amount between 0.05 and 2.5% v/v of the vaccine of a glycol ether-based surfactant;
- and
- buffered saline in a quantity sufficient to make volume.
8 more elements
A method for producing an immune response in a cat which method comprises administering to said cat an effective amount of a vaccine comprising:
- (a) an immunologically effective amount of an FeLV antigen;
- (b) an immunopotentiating amount of an immunostimulating glycopeptide, wherein said glycopeptide is a compound of the formula ##STR6## wherein R and R.sup.1 are the same or different and are hydrogen or acyl containing from 1 to 22 carbon atoms;
- R.sup.2 is an unsubstituted or substituted alkyl radical containing from 1 to 22 carbon atoms, or an unsubstituted or substituted aryl radical containing from 6 to 10 carbon atoms;
- R.sup.3 is hydrogen, alkyl, or aryl of 7 to 10 carbon atoms;
- R.sup.4 is hydrogen or alkyl;
- X is alanyl, valyl, leucyl, isoleucyl, .alpha.-aminobutyryl, threonyl, methionyl, cysteinyl, glutamyl, glutaminyl, aspartyl, phenylalanyl, tyrosyl, tryptophanyl, lysyl, ornithinyl, arginyl, histidyl, asparginyl, prolyl, hydroxyprolyl, seryl, or glycyl;
- R.sup.5 and R.sup.6 are the same or different and are a carboxyl group, a carboxyl group esterified with a lower alkanol, or a carbamoyl group, which, on the nitrogen atom, is unsubstituted or mono-substituted or di-substituted by alkyl, aryl, aralkyl, alkylidene, or carbamoylmethyl;
- (c) a multi-phase-forming amount between 0.2 and 49% v/v of the vaccine of a non-toxic polyoxypropylene-polyoxyethylene block polymer, wherein said block polymer is liquid over a temperature range between about 15.degree.-40.degree. C., has a polyoxypropylene midsection of molecular weight between about 2250 and 4300, and has polyoxyethylene in an amount between about 1 and 30% of the block polymer;
- (d) a multi-phase-stabilizing amount between 0.05 and 2.5% v/v of the vaccine of a glycol ether-based surfactant;
- and
- (e) buffered saline in a quantity sufficient to make volume.
8 more elements
A vaccine for immunizing a cat against feline leukemia virus, which vaccine comprises:
- (a) an immunologically effective amount of an FeLV antigen derived from inactivated R-FeLV virus grown in NCE-F161 cells;
- (b) 0.001 to 5% (w/v) N-acetylmuramyl-L-threonyl-D-isoglutamine;
- (c) 2.5% (w/v) polyoxypropylene-polyoxyethylene block polymer having a polyoxypropylene midsection of molecular weight 3,250 wherein polyoxyethylene comprises 10% of the polymer;
- (d) 0.2-1% (w/v) polyoxyethylene 20 sorbitan monooleate surfactant;
- and
- (e) phosphate-buffered saline.
3 more elements
A vaccine for immunizing a cat against feline leukemia virus, which vaccine comprises:
- a. an immunologically effective amount of a FeLV antigen derived from inactivated R-FeLV virus grown in NCE-F161 cells;
- b. 0.001 to 5% (w/v) N-acetylmuramyl-L-threonyl-D-isoglutamine;
- c. 2.5% (v/v) polyoxypropylene-polyoxyethylene block polymer having a polyoxypropylene midsection of molecular weight 3,250 and a polyoxyethylene component comprising 10% of the total polymer;
- d. 0.2-1% (v/v) polyoxyethylene 20 sorbitan monooleate surfactant;
- and
- e. phosphate-buffered saline.
3 more elements
A vaccine for immunizing a cat against feline leukemia virus, which vaccine comprises:
- a. an immunologically effective amount of a FeLV antigen derived from inactivated R-FeLV virus grown in NCE-F161 cells;
- b. 0.003% (w/v) N-acetylmuramyl-L-threonyl-D-isoglutamine;
- c. 2.5% (v/v) polyoxypropylene-polyoxyethylene block polymer having a polyoxypropylene midsection of molecular weight 3,250 and a polyoxyethylene component comprising 10% of the total polymer;
- d. 0.2-1% (v/v) polyoxyethylene 20 sorbitan monooleate surfactant;
- and
- e. phosphate-buffered saline.
3 more elements
Dependencies are inferred from the claim text.